Key Points
- On March 17 CEO Eric Venker sold 200,000 shares at an average price of $28.24 for $5.65 million, leaving him with 1,647,546 shares and reducing his ownership by 10.83%.
- This trade is part of a series of insider sales since December 23 — a total of **875,000 shares** sold across five transactions for roughly $21.5 million in proceeds.
- Roivant shares trade around $27.80 (12‑month range $8.73–$30.33) with a market cap near $19.9 billion, and analysts hold a consensus Moderate Buy rating with a $28.81 target price.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the company's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $28.24, for a total value of $5,648,000.00. Following the completion of the sale, the chief executive officer owned 1,647,546 shares in the company, valued at $46,526,699.04. This trade represents a 10.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Eric Venker also recently made the following trade(s):
- On Friday, February 13th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00.
- On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $21.92, for a total value of $4,384,000.00.
- On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00.
- On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.45, for a total transaction of $4,490,000.00.
Roivant Sciences Price Performance
Shares of Roivant Sciences stock opened at $27.80 on Friday. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $30.33. The stock has a market capitalization of $19.90 billion, a P/E ratio of -23.76 and a beta of 1.17. The company has a 50-day simple moving average of $25.80 and a 200 day simple moving average of $21.08.
Analyst Ratings Changes
A number of equities research analysts recently commented on the company. HC Wainwright increased their price target on Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. TD Cowen restated a "buy" rating on shares of Roivant Sciences in a report on Wednesday, March 4th. Guggenheim raised their target price on Roivant Sciences from $28.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Leerink Partners lifted their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, December 15th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Roivant Sciences has an average rating of "Moderate Buy" and a consensus target price of $28.81.
Check Out Our Latest Research Report on Roivant Sciences
Institutional Trading of Roivant Sciences
Institutional investors have recently bought and sold shares of the business. Jones Financial Companies Lllp grew its stake in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock worth $25,000 after purchasing an additional 1,148 shares during the period. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP increased its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after acquiring an additional 583 shares during the last quarter. Bessemer Group Inc. boosted its stake in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Finally, Kestra Advisory Services LLC bought a new stake in Roivant Sciences in the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
